Mintel forecasts GLP-1-driven shift to consumer-led beauty systems

Mintel’s Global Predictions 2027 report makes one directional call: the next wave of beauty growth will come from consumer-built systems, not from a single face-focused category, and it identifies increased GLP-1–based weight-loss drug use as an influence.

The consumer insights firm says those systems will extend beyond the face and organize products, services and data around four aspirations: “Look Well for Longer,” “Feel Well,” “Stay Protected” and “Feel Confident.”

This is a market forecast, not a clinical study or trial. The announcement discloses no participant cohort, survey method, market size, GLP-1 adoption rate or company forecast. Nor does it link GLP-1 use to a clinical endpoint involving skin health.

What is changing in Mintel’s 2027 forecast?

Mintel frames the change as a reversal of the commercial model that shaped the past decade. Under that model, the brand sat at the center and the consumer orbited it. Mintel says “the pull has reversed” and that “the consumer is the sun.”

In the proposed model, the consumer sets the objective and the market organizes around it. Products, services and data no longer operate as disconnected category pieces; they become part of a system judged against the result the consumer wants.

A Mintel statement defines that organizing force: “Around them turn products, services and data, held close or released by a single force: results.”

The company also expects category boundaries to erode as behavior shifts from the pattern that powered the previous decade toward goals and the systems consumers build to pursue them. Mintel’s forecast therefore concerns both the products a company offers and the relationships among those products, the services around them and the data used to support them.

What do the four consumer goals mean?

Mintel uses four phrases to define the desired outcomes:

• Look Well for Longer places duration at the center of the appearance goal rather than concentrating on an immediate result.
• Feel Well broadens the intended outcome beyond visible appearance to include how the consumer feels.
• Stay Protected treats protection as a continuing objective in its own right.
• Feel Confident adds emotional confidence to the desired result rather than leaving appearance as the sole measure of success.

Together, the goals describe a wider beauty proposition. They also give the emerging system a test: whether its combination of products, services and data supports the consumer’s objective. The report does not assign a product, service or data set to any individual goal.

Mintel links this environment to increased GLP-1 use among people taking weight-loss drugs, describing a “new beauty universe.” The announcement does not specify how GLP-1 changes appearance, routines, spending or category demand. It supports a strategic forecast about market organization, not a quantified causal claim about medication use.

What does this change for beauty brands?

It changes the unit around which a brand must organize. Under Mintel’s model, a company cannot treat products from separate beauty or personal-care categories as the end of the strategy. It must assemble them into a results-led system directed at a defined consumer goal.

That approach also changes how brands relate to consumers. The brand no longer occupies the center of the relationship; the consumer does. Mintel’s description of products, services and data turning around the consumer makes clear that the organizing logic runs from the desired result back to the supporting components.

For consumers, the forecast implies more cross-category propositions. Instead of choosing among isolated offerings, they may encounter systems that combine relevant products, services and information around a shared objective. The practical question for brand teams is not which single category will grow fastest, but which consumer outcome their combined offer can credibly support.

What does the forecast actually establish?

The report establishes a thesis and a time horizon, not a measured market outcome. The year 2027 identifies when Mintel expects the model to matter; it does not specify an adoption rate, revenue contribution, consumer segment or commercial return. The announcement also names no participating company, product or trial capable of testing the forecast.

For dermatology audiences, the distinction matters. Mintel does not present evidence that GLP-1 therapy improves acne, eczema, psoriasis or any other skin condition, and its four goals are consumer aspirations rather than clinical endpoints. The report should therefore guide market analysis without being interpreted as medical guidance or as proof of a treatment-related beauty effect.

If Mintel’s thesis holds, beauty competition in 2027 will depend less on ownership of a single category and more on the ability to build integrated, results-led systems around the four consumer goals in a market influenced by GLP-1 use.